International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

BMS Press Release Graphic

Bristol Myers Squibb has announced the U.S. Food and Drug Administration’s (FDA) approval of Sotyktu™(deucravacitinib), an oral treatment for adults with moderate to severe plaque psoriasis. Sotyktu™ is the only approved TYK2 inhibitor worldwide and the first improvement in oral treatment for moderate to severe plaque psoriasis in nearly ten years. The approval follows the results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which proved the efficacy of once-daily Sotyktu compared to placebo and twice-daily Otezla® (apremilast) in achieving clearer skin. IPC Councilor April Armstrong, MD, MPH, was quoted in the press release stating, “Sotyktu has the potential to become the new standard of care oral treatment for people with moderate to severe plaque psoriasis, given its profile in helping patients achieve clearer skin as demonstrated in the POETYK PSO clinical program.”

Bristol myers squibb logo small
Categories
Tags
Recent Posts
BIOMAP Collaboration Update A Systemic Review on Biomarkers

BIOMAP Collaboration Update: A Systemic Review on Biomarkers

BMS Press Release Graphic

U.S. Food and Drug Administration Approves Sotyktu™(deucravacitinib)

Blog - Commentary - Alexander Egeberg - graphic

Commentary: Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis

Also Read

2022 SPIN Congress Report Blog Graphic
Deepak Balak

Focus on Psoriasis: A Report from the 7th Congress of the Skin Inflammation & Psoriasis International Network (SPIN) Meeting

The Society of Investigative Dermatology (SID) Annual Meeting returned to an in-person format in 2022 for the first time in two years. The following congress report includes a summary of the Eugene Farber lecture, three IPC lectures, and seven IPC poster presentations, all with a focus on psoriasis. You can download the full report or read on for a brief look at some of the highlights.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.